within Pharmacolibrary.Drugs.ATC.S;

model S01LA01
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 5.4833333333333336e-05,
    adminDuration  = 600,
    adminMass      = 6 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.00017999999999999998,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.00029,
    k12             = 4.18,
    k21             = 4.18
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>S01LA01</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Verteporfin is a photosensitizing agent used in photodynamic therapy to treat neovascular (wet) age-related macular degeneration and pathological myopia. It is approved and used clinically for ocular neovascular conditions.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in adults aged 18-85 years without significant comorbidities after intravenous infusion over 10 minutes.</p><h4>References</h4><ol><li><p>Kaur, IP, &amp; Kakkar, S (2014). Nanotherapy for posterior eye diseases. <i>Journal of controlled release : official journal of the Controlled Release Society</i> 193 100–112. DOI:<a href=&quot;https://doi.org/10.1016/j.jconrel.2014.05.031&quot;>10.1016/j.jconrel.2014.05.031</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/24862316/&quot;>https://pubmed.ncbi.nlm.nih.gov/24862316</a></p></li><li><p>Keam, SJ, et al., &amp; Curran, MP (2004). Spotlight on verteporfin in subfoveal choroidal neovascularisation. <i>Drugs &amp; aging</i> 21(3) 203–209. DOI:<a href=&quot;https://doi.org/10.2165/00002512-200421030-00005&quot;>10.2165/00002512-200421030-00005</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/14979737/&quot;>https://pubmed.ncbi.nlm.nih.gov/14979737</a></p></li><li><p>Keam, SJ, et al., &amp; Curran, MP (2003). Verteporfin : a review of its use in the management of subfoveal choroidal neovascularisation. <i>Drugs</i> 63(22) 2521–2554. DOI:<a href=&quot;https://doi.org/10.2165/00003495-200363220-00016&quot;>10.2165/00003495-200363220-00016</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/14609361/&quot;>https://pubmed.ncbi.nlm.nih.gov/14609361</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end S01LA01;
